Riskpilot← Back to searchSign inGet full accessMälaviken Medicin AB
ABActiveOrg 5567060008Tussilagovägen 10Medical specialists activities · NACE 8622Est. 20060 employees
Revenue 2025
SEK 1,2M
-12% vs 2024
EBITDA margin
21.8%
+39% vs 2024
Equity ratio
78.8%
Financial strength
Net profit 2025
SEK 143K
+55% vs 2024
| Revenue | SEK 1,2M | -12% |
| EBITDA | SEK 251K | +39% |
| Net profit | SEK 143K | +55% |
| Total assets | SEK 2,8M | +4% |
| Equity | SEK 2,2M | +7% |
| Employees | 0 | — |
Legal name
Mälaviken Medicin AB
Org number
5567060008
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
21 juni 2006
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva medicinsk konsultverksamhet, utbildning och föreläsningar inom vårdsektorn, förvaltning av värdepapper samt dämed förenlig verksamhet.
Address
Tussilagovägen 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 154 | 1 846 | 1 649 | 1 305 | 1 153 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 114 | 699 | 549 | 181 | 251 |
| Depreciation & amort. | −3 | −1 | −0 | −0 | −40 |
| EBIT | 1 111 | 698 | 549 | 181 | 211 |
| Net financials | — | 40 | −337 | −143 | −67 |
| Profit before tax | 840 | 737 | 380 | 145 | 200 |
| Tax | −181 | −153 | −114 | −53 | −57 |
| Net profit | 659 | 584 | 266 | 92 | 143 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 303 | 3 506 | 2 790 | 2 646 | 2 758 |
| Equity | 2 737 | 2 922 | 2 188 | 2 030 | 2 173 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 296 | 314 | 332 | 347 | 315 |
| Total debt | 296 | 314 | 332 | 347 | 315 |
EBITDA margin
21.8%
This company
15.8%
Market median
+38% vs market
20212025
Equity ratio
78.8%
This company
38.2%
Market median
+106% vs market
20212025
Return on equity
6.6%
This company
18.4%
Market median
-64% vs market
20212025
Net profit margin
12.4%
This company
8.1%
Market median
+53% vs market
20212025
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
20212025
Debt / equity
0.27×
This company
0.62×
Market median
+56% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KG | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mälaviken Medicin AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kjell Gunnar Andersson | Audit | 0 companies |
| Eva Carina Ringqvist Gunnerek | Board of Directors | 0 companies |
| Mimmi Inger Maria C Lindqvist | Deputy Board Member | 0 companies |